Stocks
Immuneering CorporationIMRX
NASDAQHealthcareBiotechnology$3.73
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel therapies for cancer and other diseases by targeting the MAPK signaling pathway. Its lead product candidates are designed to treat solid tumors with specific genetic mutations, and it is advancing a pipeline of orally available small molecules. Investors track the company for its potential in precision oncology and its progress through clinical trials.
52W Range: $3.38-$8.48
Congressional Interest in Immuneering Corporation (IMRX)
No congressional trades have been disclosed for Immuneering Corporation (IMRX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading IMRX?
No congressional trades found for this stock.